Divalproex Sodium
Product Images NDC 53808-0357

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 53808-0357). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (3cd35eb6 Df66 4848 86dd F1fa47731057 01)

Chemical structure diagram of divalproex sodium showing its polymeric form with sodium ions and branched alkyl chains. The image depicts the molecular arrangement with carboxylate groups and hydrocarbon side chains characteristic of this compound.*

FDA Label Image

Divalproex Figure 1 (3cd35eb6 Df66 4848 86dd F1fa47731057 02)

A bar graph comparing percentage outcomes between placebo (PBO) and Divalproex sodium delayed-release tablets (DVPX) across two studies labeled Study 1 (YMRS) and Study 2 (MRS). The bars show higher percentages for DVPX (60% and 58%) versus placebo (26% and 29%) in each study, respectively. Percentages are shown on the vertical axis from 0% to 70%.*

FDA Label Image

Divalproex Figure 2 (3cd35eb6 Df66 4848 86dd F1fa47731057 03)

A bar chart comparing mean dose values between placebo and Divalproex Sodium delayed-release tablets in two studies. The x-axis shows Study 1 and Study 2 groups with placebo and treatment bars. The y-axis represents dose values, with higher bars for placebo in both studies compared to Divalproex Sodium delayed-release. Footnotes note mean doses of 1087 mg/day for Study 1 and doses of 500 or 1000 mg/day for Study 2.*

FDA Label Image

Divalproex Figure 3 (3cd35eb6 Df66 4848 86dd F1fa47731057 04)

A line graph comparing the percentage reduction in CPS rate between Divalproex Sodium delayed-release and placebo. The x-axis represents the percentage of patients, and the y-axis shows the percent reduction in CPS rate with a scale indicating improvement above and worsening below a no change baseline. Two lines depict Divalproex Sodium delayed-release and placebo outcomes over the patient percentage range.*

FDA Label Image

Divalproex Figure 4 (3cd35eb6 Df66 4848 86dd F1fa47731057 05)

A chart showing the relationship between the percentage of patients and the percentage reduction in CPS rate for high dose and low dose Divalproex Sodium delayed release. The y-axis represents the percentage reduction in CPS rate from -100% worsening to 100% improvement, while the x-axis represents the percentage of patients. Two curves compare high dose (solid line) and low dose (dashed line) Divalproex Sodium delayed release effects.*

FDA Label Image

Label Image For 250mg (Divalproex 250mg(lupin))

Label for Divalproex Sodium 250 mg tablets, prescription only, with a quantity of 30. The label includes lot number 3902665, expiration date 06/3010, and indicates the product is packaged by DOH Central Pharmacy in Tallahassee, FL 32304. A barcode and UPC number 368180266013 are also visible.*

FDA Label Image

Label Image For 500mg (Divalproex 500mg(lupin))

Label for Divalproex Sodium 500 mg tablets, quantity 30, labeled RX only. Manufactured or packaged by DOH Central Pharmacy, Tallahassee, FL 32304. The label includes lot number 3904340 and an expiration date of 06/3010. A UPC barcode is also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.